A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

Key facts

Sponsor

GC Biopharma Corp

Principal Investigator

Eun-Jin Choi

Daegu Catholic University Medical Center

Intervention

MG1113(biological)

Enrollment

15 target

Eligibility

19-60 years · MALE

Timeline

2022 – 2024

Study locations (1)

• GC Biopharma Corp., Yongin-si, Gyeonggi-do, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Severe hemophilia A

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNANCT06816953
  Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII Prophylaxis
  Chulalongkorn University
• RECRUITINGPHASE3NCT06142552
  Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
  Jiangsu Gensciences lnc.
• ACTIVE NOT RECRUITINGPHASE3NCT06224907
  Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
  BioMarin Pharmaceutical
• RECRUITINGNCT05981274
  A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)
  Tri-Service General Hospital
• ENROLLING BY INVITATIONNCT05768386
  A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
  BioMarin Pharmaceutical
• RECRUITINGPHASE4NCT04690322
  POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
  University of Texas Southwestern Medical Center

See all trials for Severe hemophilia A →